Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ASP006
MIFTS: 67

Aspergillosis

Categories: Genetic diseases, Immune diseases, Infectious diseases, Rare diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Aspergillosis

About this section

MalaCards integrated aliases for Aspergillosis:

Name: Aspergillosis 58 12 77 54 60 56 44 45 15 17 74 3
Aspergillosis, Susceptibility to 58 30 13 6 41
Infection Due to Aspergillus 12

Characteristics:

Orphanet epidemiological data:

60
aspergillosis
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Infectious diseases
Anatomical: Immune diseases Respiratory diseases
See all MalaCards categories (disease lists)
ICD10: 34 35
Orphanet: 60  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:13564
OMIM 58 614079
ICD9CM 36 117.3
MeSH 45 D001228
NCIt 51 C2886
SNOMED-CT 69 65553006
ICD10 34 B44 B44.9
MESH via Orphanet 46 D001228
ICD10 via Orphanet 35 B44.0 B44.1 B44.2 more
UMLS via Orphanet 75 C0004030
Orphanet 60 ORPHA1163
UMLS 74 C0004030
Sources

Summaries for Aspergillosis

About this section
NIH Rare Diseases : 54 Aspergillosis is an infection, growth, or allergic response caused by the Aspergillus fungus. There are several different kinds of aspergillosis. One kind is allergic bronchopulmonary aspergillosis (also called ABPA), a condition where the fungus causes allergic respiratory symptoms similar to asthma, such as wheezing and coughing, but does not actually invade and destroy tissue. Another kind of aspergillosis is invasive aspergillosis. This infection usually affects people with weakened immune systems due to cancer, AIDS, leukemia, organ transplantation, chemotherapy, or other conditions or events that reduce the number of normal white blood cells. In this condition, the fungus invades and damages tissues in the body. Invasive aspergillosis most commonly affects the lungs, but can also cause infection in many other organs and can spread throughout the body (commonly affecting the kidneys and brain).Aspergilloma, a growth (fungus ball) that develops in an area of previous lung disease such as tuberculosis or lung abscess, is a third kind of aspergillosis. This type of aspergillosis is composed of a tangled mass of fungus fibers, blood clots, and white blood cells. The fungus ball gradually enlarges, destroying lung tissue in the process, but usually does not spread to other areas.

MalaCards based summary : Aspergillosis, also known as aspergillosis, susceptibility to, is related to invasive aspergillosis and allergic bronchopulmonary aspergillosis, and has symptoms including fever and pruritus. An important gene associated with Aspergillosis is CLEC7A (C-Type Lectin Domain Containing 7A), and among its related pathways/superpathways are Innate Immune System and PEDF Induced Signaling. The drugs Miconazole and Voriconazole have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and liver, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 An opportunistic mycosis that involves a spectrum of diseases of humans and animals caused by members of the genus Aspergillus infecting lungs, brain, kidney, heart, bone, eyes, sinuses, skin and gastrointestinal tract. It is a serious illnesses in people with a weakened immune system.

OMIM : 58 Aspergillus species are ubiquitous in nature and cause a wide spectrum of diseases, including saprophytic colonization of existing cavities (aspergilloma), allergic asthma, hypersensitivity pneumonitis, allergic bronchopulmonary aspergillosis, and disseminated disease associated with high mortality rates in patients with hematologic malignancies and recipients of solid organs and stem cell transplantations. Immunocompetent and nonatopic individuals are relatively resistant to infection, and disease occurs in the setting of host damage. Association of persistent inflammation with intractable infection is common in nonneutropenic patients after hematopoietic stem cell transplantation, as well as in allergic fungal diseases. The pathophysiology underlying Aspergillus infection highlights the bipolar nature of the inflammatory process in infection, in which early inflammation prevents or limits infection, but an uncontrolled response may oppose disease eradication (summary by Cunha et al., 2010). For information on familial occurrence of allergic bronchopulmonary aspergillosis, see 103920. (614079)

MedlinePlus : 44 Aspergillosis is a disease caused by a fungus (or mold) called Aspergillus. The fungus is very common in both indoors and outdoors. Most people breathe in the spores of the fungus every day without being affected. But some people get the disease. It usually occurs in people with lung diseases or weakened immune systems. There are different kinds of aspergillosis. One kind is allergic bronchopulmonary aspergillosis (also called ABPA). Symptoms of ABPA include wheezing and coughing. ABPA can affect healthy people but it is most common in people with asthma or cystic fibrosis. Another kind is invasive aspergillosis, which damages tissues in the body. It usually affects the lungs. Sometimes it can also cause infection in other organs and spread throughout the body. It affects people who have immune system problems, such as people who have had a transplant, are taking high doses of steroids, or getting chemotherapy for some cancers. Your doctor might do a variety of tests to make the diagnosis, including a chest x-ray, CT scan of the lungs, and an examination of tissues for signs of the fungus. Treatment is with antifungal drugs. If you have ABPA, you may also take steroids. Centers for Disease Control and Prevention

CDC : 3 Aspergillosis is an infection caused by Aspergillus, a common mold (a type of fungus) that lives indoors and outdoors. Most people breathe in Aspergillus spores every day without getting sick. However, people with weakened immune systems or lung diseases are at a higher risk of developing health problems due to Aspergillus. The types of health problems caused by Aspergillus include allergic reactions, lung infections, and infections in other organs.

Wikipedia : 77 Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus... more...

Sources

Related Diseases for Aspergillosis

About this section

Diseases in the Aspergillosis family:

Invasive Aspergillosis

Diseases related to Aspergillosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 542)
# Related Disease Score Top Affiliating Genes
1 invasive aspergillosis 33.8 CLEC7A IFNG MBL2 SFTPD TLR2 TLR4
2 allergic bronchopulmonary aspergillosis 33.7 CCL17 CFTR IL4 IL5 MBL2 SFTPA2
3 candidiasis 31.1 CLEC7A IFNG IL10 MBL2
4 cystic fibrosis 31.1 CFTR ELANE MBL2 SFTPD TLR4
5 cryptococcosis 30.7 IFNG IL4 MBL2 TLR9
6 hematopoietic stem cell transplantation 30.7 CLEC7A IFNG IL10 TNF
7 granulomatosis with polyangiitis 30.4 ELANE TLR2 TLR9
8 bronchiectasis 30.3 CFTR ELANE MBL2 TLR2
9 endocarditis 30.3 IL10 TLR2 TNF
10 hyper ige syndrome 30.3 IFNG IL4 TLR2
11 graft-versus-host disease 30.2 IFNG IL10 TNF
12 allergic rhinitis 30.2 IFNG IL10 IL4 IL5
13 respiratory failure 30.2 ELANE SFTPD TNF
14 acute respiratory distress syndrome 30.1 ELANE SFTPD TNF
15 osteomyelitis 30.1 IFNG IL10 TNF
16 pulmonary disease, chronic obstructive 30.1 CFTR ELANE SFTPD TLR2 TNF
17 pneumocystosis 30.0 CLEC7A SFTPD TNF
18 cutaneous t cell lymphoma 30.0 CCL17 IFNG IL4
19 bronchiolitis obliterans 30.0 IFNG IL10 TNF
20 neuritis 30.0 IFNG IL4 TNF
21 systemic scleroderma 30.0 IFNG SFTPD TLR9
22 legionellosis 30.0 TLR2 TLR4 TNF
23 staphylococcal toxic shock syndrome 29.9 IFNG TNF
24 septic arthritis 29.9 TLR2 TLR4 TLR9
25 bacterial pneumonia 29.8 ELANE SFTPD TLR4 TLR9
26 ulcerative colitis 29.8 IFNG IL10 TLR4 TNF
27 arthritis 29.8 CSF2 IFNG IL10 TNF
28 eosinophilic pneumonia 29.8 CCL17 CSF2 IL5 SFTPD
29 aseptic meningitis 29.8 IFNG IL10 TNF
30 paranasal sinus disease 29.8 IFNG IL10 IL4 IL5
31 pyelonephritis 29.8 IL10 TLR4 TNF
32 acute graft versus host disease 29.7 IFNG IL10 IL4 TNF
33 acute pancreatitis 29.7 CFTR ELANE IL10
34 ige responsiveness, atopic 29.7 IFNG IL10 IL4 IL5
35 colitis 29.7 IFNG IL10 IL4 TLR4 TLR9 TNF
36 dermatitis 29.7 CCL17 IFNG IL4 IL5 TLR9
37 pulmonary eosinophilia 29.7 CCL17 IL4 IL5 SFTPD
38 severe acute respiratory syndrome 29.7 CD209 IFNG TNF
39 churg-strauss syndrome 29.6 CCL17 IL10 IL5 TNF
40 dengue hemorrhagic fever 29.6 CD209 IFNG IL10 TNF
41 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 29.6 CD209 IFNG IL10 IL4
42 chronic graft versus host disease 29.6 IFNG IL10 TNF
43 plasmodium falciparum malaria 29.6 IFNG IL10 TLR9 TNF
44 allergic asthma 29.6 CCL17 IFNG IL10 IL4 IL5
45 hypereosinophilic syndrome 29.6 CCL17 CSF2 IL4 IL5
46 interstitial lung disease 29.5 CCL17 IFNG IL10 IL4 SFTPD TNF
47 lepromatous leprosy 29.5 IFNG IL10 TLR2 TNF
48 penicilliosis 29.5 TLR2 TLR4 TNF
49 acquired immunodeficiency syndrome 29.5 CCL3 CSF2 IFNG IL10 TNF
50 gastroenteritis 29.4 IL10 IL4 IL5 TNF

Comorbidity relations with Aspergillosis via Phenotypic Disease Network (PDN):


Bronchiectasis Bronchitis
Deficiency Anemia Heart Disease
Postinflammatory Pulmonary Fibrosis Respiratory Failure

Graphical network of the top 20 diseases related to Aspergillosis:



Diseases related to Aspergillosis
Sources

Symptoms & Phenotypes for Aspergillosis

About this section

Clinical features from OMIM:

614079

UMLS symptoms related to Aspergillosis:


fever, pruritus

MGI Mouse Phenotypes related to Aspergillosis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.34 CCL17 CFTR CLEC7A CSF2 ELANE IFNG
2 immune system MP:0005387 10.27 CCL17 CFTR CLEC7A CSF2 ELANE IFNG
3 homeostasis/metabolism MP:0005376 10.25 CFTR CLEC7A CSF2 ELANE IFNG IL10
4 digestive/alimentary MP:0005381 10.16 CFTR CLEC7A IFNG IL10 IL4 IL5
5 liver/biliary system MP:0005370 9.92 CFTR IFNG IL10 IL4 IL5 TLR2
6 neoplasm MP:0002006 9.86 CSF2 ELANE IFNG IL10 IL5 TLR2
7 renal/urinary system MP:0005367 9.7 CSF2 IFNG IL4 MBL2 TLR2 TLR4
8 reproductive system MP:0005389 9.61 CFTR CSF2 IFNG IL10 IL4 IL5
9 respiratory system MP:0005388 9.4 CFTR CLEC7A CSF2 IFNG IL10 IL4
Sources

Drugs & Therapeutics for Aspergillosis

About this section

Drugs for Aspergillosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 169)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
2
Voriconazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 137234-62-9 71616
3
Amphotericin B Approved, Investigational Phase 4,Phase 2,Phase 3 1397-89-3 14956 5280965
4
Caspofungin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 179463-17-3, 162808-62-0 2826718 468682
5
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
6
Itraconazole Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1 84625-61-6 55283
7
Anidulafungin Approved, Investigational Phase 4,Phase 3,Phase 2 166663-25-8 166548
8
Micafungin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 235114-32-6 477468 3081921
9
Nevirapine Approved Phase 4 129618-40-2 4463
10
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
11
Ritonavir Approved, Investigational Phase 4,Phase 3 155213-67-5 392622
12
Posaconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 171228-49-2 147912
13
Prednisone Approved, Vet_approved Phase 4,Phase 1,Phase 2 53-03-2 5865
14
Mycophenolic acid Approved Phase 4,Phase 1 24280-93-1 446541
15
Omalizumab Approved, Investigational Phase 4 242138-07-4
16
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Not Applicable 50-14-6 5280793
17
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 1406-16-2
18
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Not Applicable 67-97-0 5280795 6221
19
Calcium Approved, Nutraceutical Phase 4,Phase 2,Phase 3,Not Applicable 7440-70-2 271
20
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
21 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
22 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Antiprotozoal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
30 Antiparasitic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
31 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
32 Liposomal amphotericin B Phase 4,Phase 2,Phase 3
33 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Early Phase 1
34 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
35 Antitussive Agents Phase 4
36
Hydroxyitraconazole Phase 4,Phase 2,Phase 3,Not Applicable,Early Phase 1
37 Nutrients Phase 4,Phase 2,Phase 3,Not Applicable
38 Vitamins Phase 4,Phase 2,Phase 3,Not Applicable
39 Trace Elements Phase 4,Phase 2,Phase 3,Not Applicable
40 Calciferol Phase 4,Phase 2,Phase 3,Not Applicable
41 Bone Density Conservation Agents Phase 4,Phase 2,Phase 3,Not Applicable
42 Ergocalciferols Phase 4,Phase 2,Phase 3,Not Applicable
43 Vitamin D2 Phase 4,Phase 2,Phase 3,Not Applicable
44 Micronutrients Phase 4,Phase 2,Phase 3,Not Applicable
45 Calcium, Dietary Phase 4,Phase 2,Phase 3,Not Applicable
46 Anti-HIV Agents Phase 4,Phase 3
47 Atazanavir Sulfate Phase 4
48 Reverse Transcriptase Inhibitors Phase 4
49 Anti-Retroviral Agents Phase 4,Phase 3
50 Cytochrome P-450 CYP3A Inducers Phase 4

Interventional clinical trials:

(show top 50) (show all 196)
# Name Status NCT ID Phase Drugs
1 Voriconazole for IPA in Chinese Patients With COPD Unknown status NCT02234739 Phase 4 Voriconazole
2 Value of Amphotericin B Inhalation for Prophylaxis of Invasive Pulmonary Aspergillosis After Renal Transplantation Unknown status NCT00986713 Phase 4 Amphotericin B
3 Efficacy and Safety of Caspofungin for Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease Unknown status NCT01499433 Phase 4 caspofungin
4 Efficacy Of Itraconazole In Chronic Cavitary Pulmonary Aspergillosis Completed NCT01259336 Phase 4 Itraconazole;treatment in cavitary pulmonary aspergillosis
5 COMBISTRAT: AmBisome® in Combination With Caspofungin for the Treatment of Invasive Aspergillosis Completed NCT00334412 Phase 4 Ambisome;caspofungin
6 A Study To Assess The Anidulafungin And Voriconazole Concentration In Lung Following Intravenous Administration In Healthy Subjects Completed NCT00940017 Phase 4 anidulafungin and voriconazole
7 A Study of the Efficacy and Safety of Voriconazole for the Treatment of Fungal Infections Completed NCT00647907 Phase 4 Voriconazole
8 Pharmacokinetics of Micafungin in Patients of Intensive Care Units Completed NCT02164890 Phase 4
9 VITamine D Supplementation in RenAL Transplant Recipients - VITALE Completed NCT01431430 Phase 4 Cholecalciferol 100 000 UI;Cholecalciferol 12 000 UI
10 Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT) Completed NCT00552240 Phase 4 tenofovir DF 300 mg QD;tenofovir DF 300 mg QD;emtricitabine 200 mg QD;emtricitabine 200 mg QD;Nevirapine 200 mg BID;Atazanavir 300 mg;Ritonavir 100 mg
11 Posaconazole for the Prevention of Influenza-associated Aspergillosis in Critically Ill Patients Recruiting NCT03378479 Phase 4 SOC +Posaconazole 18 MG/ML (milligram/milliliter)
12 CYP2C19 Genotype-Specific Dosing Plus TDM on Reaching Therapeutic Voriconazole Blood Levels Recruiting NCT03731169 Phase 4 Standard of Care
13 King's Invasive Aspergillosis Study II Active, not recruiting NCT02875743 Phase 4 Posaconazole
14 Posaconazole Pharmacokinetics in Patients Receiving Chemotherapy or Stem Cell Transplants Not yet recruiting NCT03717623 Phase 4 Posaconazole pharmacokinetics
15 Study to Test the Combination of Voriconazole and Anidulafungin in Patients Who Have, or Are Thought to Have, Invasive Aspergillosis and Who Are Unable to Take a Common Antifungal Therapy (Polyene) Terminated NCT00620074 Phase 4 voriconazole;anidulafungin
16 Post Marketing Study to Evaluate the Efficacy and Safety of Micafungin Treatment on Invasive Aspergillosis Terminated NCT02646774 Phase 4 Micafungin
17 An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA) Terminated NCT00787917 Phase 4 Omalizumab;Placebo;Itraconazole
18 Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp Terminated NCT02646800 Phase 4 Micafungin
19 Comparison of 2 Antifungal Treatment (Empirical Versus Pre-Empirical) Strategies in Prolonged Neutropenia Terminated NCT00190463 Phase 4 Amphotericin B
20 Evaluation of Antifungal Prophylaxis on Graft-versus-host Disease (GVHD) Patients Terminated NCT01282879 Phase 4 Itraconazole
21 A Study to Evaluate the Effectiveness of Voriconazole + Micafungin Versus Voriconazole Alone for Invasive Aspergillosis Withdrawn NCT00423163 Phase 4 micafungin;voriconazole
22 Posaconazole as Salvage Therapy for Aspergillus Pulmonary Infection. Withdrawn NCT02020213 Phase 4 Posaconazole
23 Efficacy, Safety and Pharmacokinetics of SPK-843 in the Treatment of Pulmonary Mycosis Unknown status NCT01125644 Phase 3 SPK-843
24 Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis Completed NCT00531479 Phase 3 voriconazole;anidulafungin;voriconazole
25 Voriconazole For Chronic Bronchopulmonary Aspergillosis Completed NCT00159822 Phase 2, Phase 3 Voriconazole
26 Inhalation of Liposomal Amphotericin B to Prevent Invasive Aspergillosis Completed NCT00263315 Phase 2, Phase 3 nebulised liposomal amphotericin B
27 A Multicentre Randomised Controlled Trial Comparing Two Strategies for the Diagnosis of Invasive Aspergillosis in High-risk Haematology Patients Completed NCT00163722 Phase 3
28 Trial on the Efficacy and Safety of Two Different Glucocorticoid Dose Regimens in Allergic Bronchopulmonary Aspergillosis Completed NCT00974766 Phase 2, Phase 3 Glucocorticoids;Glucocorticoids
29 A Safety & Effectiveness Study of Intravenous Anidulafungin With AmBisome® for Treatment of Invasive Aspergillosis (IA). Completed NCT00037206 Phase 2, Phase 3 Anidulafungin, VER002
30 A Study Evaluating Vitamin D in Allergic Bronchopulmonary Aspergillosis Complicating Asthma Completed NCT03133299 Phase 2, Phase 3 Glucocorticoids;Vitamin D
31 Voriconazole Versus Oral Steroids in Allergic Bronchopulmonary Aspergillosis Completed NCT01621321 Phase 2, Phase 3 Prednisolone;Voriconazole
32 Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi Completed NCT00634049 Phase 3 isavuconazole
33 A Randomized Controlled Trial of Inhaled Amphotericin B for Maintaining Remission in Allergic Bronchopulmonary Aspergillosis Completed NCT01857479 Phase 2, Phase 3 Inhaled budesonide;Inhaled amphotericin
34 Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis Completed NCT00001646 Phase 3 Voriconazole;Amphotericin B
35 Comparison of Voriconazole and Amphotericin B in Treating Patients With Aspergillosis Completed NCT00003031 Phase 3 amphotericin B deoxycholate;voriconazole
36 Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis Completed NCT00412893 Phase 3 Isavuconazole;Voriconazole
37 Study Safety/Efficacy of AmBisome Loading Dose Regimen Versus Standard AmBisome Regimen for Initial Treatment Completed NCT00158730 Phase 3 AmBisome
38 Assessing the Safety and Efficacy of MK-5592 (Posaconazole) in Japanese Participants With Fungal Infection (MK-5592-101) Completed NCT02180165 Phase 3 Posaconazole;Voriconazole
39 To Determine Whether Galactomannan Test Will Help to Detect Fungal Infections Early and Hence Start Treatment Early Completed NCT00361517 Phase 3 Amphotericin-B deoxycholate
40 Monotherapy of Itraconazole Versus Prednisolone in Allergic Bronchopulmonary Aspergillosis Completed NCT01321827 Phase 2, Phase 3 Glucocorticoids;Itraconazole
41 A Clinical Study of MK0991 (Caspofungin) in Japanese Patients With Deep-seated Candida or Aspergillus Infections (0991-062)(COMPLETED) Completed NCT00717860 Phase 3 caspofungin acetate;Comparator: Micafungin sodium
42 An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections Completed NCT00001810 Phase 3 Voriconazole
43 Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients Completed NCT00001937 Phase 3 FK463;Fluconazole
44 Open Label Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P00041) Completed NCT00034658 Phase 3 Posaconazole
45 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3 fluconazole;itraconazole
46 Pharmacokinetic Profiles of Inhaled Lipid Complex Amphotericin B (Abelcet ®) Completed NCT00177684 Phase 3 Amphotericin B
47 Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P02095) Completed NCT00034632 Phase 3 Posaconazole oral suspension
48 Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia Completed NCT01307579 Phase 3 Caspofungin Acetate;Fluconazole
49 A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection Completed NCT00784368 Phase 3 ITCZ Oral Solution;ITCZ-IV
50 An Open Label, Non-Comparative, Multicenter, Phase III Trial of the Efficacy, Safety and Toleration of Voriconazole in the Primary or Secondary Treatment of Invasive Fungal Infections Completed NCT00001757 Phase 3 Voriconazole

Search NIH Clinical Center for Aspergillosis

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: aspergillosis

Sources

Genetic Tests for Aspergillosis

About this section

Genetic tests related to Aspergillosis:

# Genetic test Affiliating Genes
1 Aspergillosis, Susceptibility to 30 CLEC1A CLEC7A
Sources

Anatomical Context for Aspergillosis

About this section

MalaCards organs/tissues related to Aspergillosis:

42
Lung, Testes, Liver, Bone, Kidney, Brain, Heart
Sources

Publications for Aspergillosis

About this section

Articles related to Aspergillosis:

(show top 50) (show all 4082)
# Title Authors Year
1
Effect of laminar air flow and building construction on aspergillosis in acute leukemia patients: a retrospective cohort study. ( 30626352 )
2019
2
Allergic bronchopulmonary aspergillosis successfully treated with mepolizumab: Case report and review of the literature. ( 30533379 )
2019
3
Voriconazole hepatotoxicity as a result of steroid withdrawal in a patient with allergic bronchopulmonary aspergillosis. ( 30537018 )
2019
4
Role of Aspergillus fumigatus-Specific IgE in the Diagnosis of Allergic Bronchopulmonary Aspergillosis. ( 30625471 )
2019
5
Allergic bronchopulmonary aspergillosis screening in bronchiectasis: is there always a precise answer to a clear question? ( 30638358 )
2019
6
Allergic bronchopulmonary aspergillosis in succession to chronic eosinophilic pneumonia. ( 30670338 )
2019
7
Pulmonary infection caused by Nocardia cyriacigeorgica in a patient with allergic bronchopulmonary aspergillosis: A case report: Erratum. ( 30681635 )
2019
8
Evaluation of 3 T lung magnetic resonance imaging in children with allergic bronchopulmonary aspergillosis: Pilot study. ( 30691671 )
2019
9
Case series of allergic bronchopulmonary aspergillosis treated successfully and safely with long-term mepolizumab. ( 30704844 )
2019
10
Prevalence of allergic bronchopulmonary aspergillosis among patients with severe bronchial asthma in a tertiary care hospital in Northern India. ( 30706871 )
2019
11
CT evaluation of hyperattenuating mucus to diagnose allergic bronchopulmonary aspergillosis in the special condition of cystic fibrosis. ( 30765182 )
2019
12
Allergic bronchopulmonary aspergillosis presumably unmasked by PD-1 inhibition. ( 30765445 )
2019
13
Successful treatment with omalizumab of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis: case reports and literature review. ( 30772479 )
2019
14
Successful control of exacerbation of Allergic Bronchopulmonary Aspergillosis due to Aspergillus terreus in a cystic fibrosis patient with short-term adjunctive therapy with voriconazole: A case report. ( 30782501 )
2019
15
Chronic pulmonary aspergillosis may cause eosinophilic granulomatosis with polyangiitis via allergic bronchopulmonary aspergillosis. ( 30800324 )
2019
16
Posaconazole for the treatment of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. ( 30805605 )
2019
17
Chronic pulmonary aspergillosis following pulmonary embolism. ( 30505676 )
2019
18
Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events. ( 30570179 )
2019
19
Utility of Serum and Bronchoalveolar Lavage Fluid Galactomannan in Diagnosis of Chronic Pulmonary Aspergillosis. ( 30626661 )
2019
20
Prevention of healthcare-associated invasive aspergillosis during hospital construction/renovation works. ( 30629998 )
2019
21
A novel monoclonal antibody against enolase antigen of Aspergillus fumigatus protects experimental aspergillosis in mice. ( 30649286 )
2019
22
'Real-life' analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study. ( 30649413 )
2019
23
Species-specific detection of medically important aspergilli by a loop-mediated isothermal amplification method in chronic pulmonary aspergillosis. ( 30649423 )
2019
24
Diagnosing invasive pulmonary aspergillosis in hematology patients: a retrospective multicenter evaluation of a novel lateral flow device. ( 30651395 )
2019
25
Invasive Pulmonary Aspergillosis in Patients with Influenza Infection: A Retrospective Study and Review of the Literature. ( 30661296 )
2019
26
APX001 Pharmacokinetic/Pharmacodynamic Target Determination against Aspergillus fumigatus in an in vivo Model of Invasive Pulmonary Aspergillosis. ( 30670426 )
2019
27
International Multicenter Experience in the Treatment Outcome of Invasive Aspergillosis in Immunocompromised Cancer Patients. ( 30671209 )
2019
28
Monitoring treatment response in chronic pulmonary aspergillosis: role of clinical, spirometric and immunological markers. ( 30685498 )
2019
29
Usefulness of animal models of aspergillosis in studying immunity against Aspergillus infections. ( 30686743 )
2019
30
Exacerbation of chronic pulmonary aspergillosis was associated with a high rebleeding rate after bronchial artery embolization. ( 30692051 )
2019
31
Invasive aspergillosis complicating treatment with tyrosine kinase inhibitors. ( 30700454 )
2019
32
Concurrent cerebral aspergillosis and abdominal mucormycosis during Ibrutinib therapy for chronic lymphocytic leukemia. ( 30703527 )
2019
33
Chronic pulmonary aspergillosis commonly complicates treated pulmonary tuberculosis with residual cavitation. ( 30705126 )
2019
34
Invasive aspergillosis manifesting as retinal necrosis in a patient treated with ruxolitinib. ( 30712951 )
2019
35
Correction: Combination Antifungal Therapy for Invasive Aspergillosis. ( 30716753 )
2019
36
A novel diagnosis scoring model to predict invasive pulmonary aspergillosis in the intensive care unit. ( 30723858 )
2019
37
Cost-effectiveness analysis of isavuconazole versus voriconazole for the treatment of patients with possible invasive aspergillosis in Sweden. ( 30744563 )
2019
38
An unusual case of cardiac aspergillosis. ( 30753391 )
2019
39
Isavuconazole brain penetration in cerebral aspergillosis. ( 30753519 )
2019
40
Use of Aspergillus fumigatus real-time PCR in bronchoalveolar lavage samples (BAL) for diagnosis of invasive aspergillosis, including azole-resistant cases, in high risk haematology patients: the need for a combined use with galactomannan. ( 30753590 )
2019
41
Invasive Aspergillosis in Pediatric Leukemia Patients: Prevention and Treatment. ( 30754630 )
2019
42
Surgical management of pulmonary aspergillosis in pediatric population. ( 30755326 )
2019
43
Subacute invasive aspergillosis in a patient with cystic fibrosis. ( 30765333 )
2019
44
Diagnostic Analysis of Computed Tomography Patterns in Patients With Invasive Pulmonary Aspergillosis After Solid-Organ Transplantation. ( 30777558 )
2019
45
CD11b Regulates Fungal Outgrowth but Not Neutrophil Recruitment in a Mouse Model of Invasive Pulmonary Aspergillosis. ( 30778357 )
2019
46
Invasive pulmonary aspergillosis in cirrhotic patients: analysis of a 10-year clinical experience. ( 30778699 )
2019
47
The Difficulty of Diagnosing Invasive Aspergillosis Initially Manifesting as Optic Neuropathy. ( 30792652 )
2019
48
Comparative Assessment of Aspergillosis by Virtual Infection Modeling in Murine and Human Lung. ( 30804941 )
2019
49
Chronic Pulmonary Aspergillosis in Patients with Underlying Respiratory Disorders in Cuba-A Pilot Study. ( 30813272 )
2019
50
The 8th Advances Against Aspergillosis (AAA) conference. ( 30816961 )
2019
Sources

Variations for Aspergillosis

About this section

ClinVar genetic disease variations for Aspergillosis:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 CLEC7A NM_197947.2(CLEC7A): c.714T> G (p.Tyr238Ter) single nucleotide variant Benign rs16910526 GRCh37 Chromosome 12, 10271087: 10271087
2 CLEC7A NM_197947.2(CLEC7A): c.714T> G (p.Tyr238Ter) single nucleotide variant Benign rs16910526 GRCh38 Chromosome 12, 10118488: 10118488
3 CLEC1A NM_016511.3(CLEC1A): c.77G> C (p.Gly26Ala) single nucleotide variant risk factor GRCh37 Chromosome 12, 10251445: 10251445
4 CLEC1A NM_016511.3(CLEC1A): c.77G> C (p.Gly26Ala) single nucleotide variant risk factor GRCh38 Chromosome 12, 10098846: 10098846
Sources

Expression for Aspergillosis

About this section
Search GEO for disease gene expression data for Aspergillosis.
Sources

Pathways for Aspergillosis

About this section

Pathways related to Aspergillosis according to GeneCards Suite gene sharing:

(show top 50) (show all 54)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 67
Show member pathways
 14.07 CCL3 CD209 CLEC7A CSF2 ELANE IFNG
2
PEDF Induced Signaling 65
Show member pathways
 13.7 CCL17 CCL3 CSF2 IFNG IL10 IL4
3
Akt Signaling 65
Show member pathways
 13.48 CCL17 CCL3 CSF2 IL10 IL4 IL5
4
Cytokine Signaling in Immune system 67
Show member pathways
 13.37 CCL3 CSF2 IFNG IL10 IL4 IL5
5
PAK Pathway 65
Show member pathways
 13.32 CCL17 CCL3 CSF2 IL10 IL4 IL5
6
Toll-like Receptor Signaling Pathway 38 1
Show member pathways
 13.24 CCL3 IFNG IL10 MBL2 SFTPA2 SFTPD
7
Th17 cell differentiation 38
Show member pathways
 12.7 IFNG IL10 IL4 IL5 TLR2 TLR4
8
Influenza A 38
Show member pathways
 12.67 CD209 IFNG IL4 TLR2 TLR4 TLR9
9
NF-kappaB Signaling 4
12.65 IFNG IL10 IL4 TLR2 TLR9 TNF
10
T cell receptor signaling pathway 38
Show member pathways
 12.53 CSF2 IFNG IL10 IL4 IL5 TNF
11
JAK-STAT signaling pathway (KEGG) 66
Show member pathways
 12.46 CSF2 IFNG IL10 IL4 IL5
12
Toxoplasmosis 38
Show member pathways
 12.37 IFNG IL10 IL4 TLR2 TLR4 TNF
13
IL-17 Family Signaling Pathways 66
Show member pathways
 12.34 CCL17 CFTR CSF2 IFNG IL4 IL5
14
Immune response IFN alpha/beta signaling pathway 23
Show member pathways
 12.31 IFNG IL10 IL4 IL5 TNF
15
C-type lectin receptor signaling pathway 38
Show member pathways
 12.31 CCL17 CD209 CLEC7A IL10 TLR9 TNF
16
Diseases associated with the TLR signaling cascade 67
Show member pathways
 12.28 TLR2 TLR4 TLR9 TNF
17
Colorectal Cancer Metastasis 65
12.28 IFNG TLR2 TLR4 TLR9 TNF
18
Phagosome 38
12.18 CD209 CLEC7A MBL2 SFTPA2 SFTPD TLR2
19
Tuberculosis 38
12.18 CD209 CLEC7A IFNG IL10 TLR2 TLR4
20
Th1 Differentiation Pathway 66
Show member pathways
 12.17 IFNG IL10 TLR2 TLR4 TLR9 TNF
21
Immune response IFN gamma signaling pathway 23
Show member pathways
 12.16 CCL17 CCL3 IFNG IL10 IL4 IL5
22
Microglia Activation During Neuroinflammation: Overview 66
Show member pathways
 12.15 CSF2 IFNG IL4 TLR2 TLR4 TNF
23
MAPK Pathway 73
Show member pathways
 12.08 IL5 TLR2 TLR4 TLR9
24
Bacterial infections in CF airways 23
Show member pathways
 12.08 CFTR IFNG IL4 SFTPD TLR2 TLR4
25
Spinal Cord Injury 1
12.07 IFNG IL4 TLR4 TNF
26
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 66
12.04 CD209 CSF2 IFNG IL10 IL4 IL5
27
Amoebiasis 38
12.01 CSF2 IFNG IL10 TLR2 TLR4 TNF
28
Hematopoietic cell lineage 38
11.97 CSF2 IL4 IL5 TNF
29
Rheumatoid arthritis 38
11.96 CCL3 CSF2 IFNG TLR2 TLR4 TNF
30
Salmonella infection (KEGG) 38
11.92 CCL3 CSF2 IFNG TLR4
31
Phagocytosis of Microbes 65
11.91 CLEC7A TLR2 TLR4 TLR9
32
Glucocorticoid receptor regulatory network 1
11.89 CSF2 IFNG IL4 IL5
33
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.88 CSF2 IFNG IL4 IL5 TNF
34
Innate Lymphoid Cell Differentiation Pathways 66
11.87 CCL3 IFNG IL10 IL4 IL5 TNF
35
Cytokine production by Th17 cells in CF (Mouse model) 23
Show member pathways
 11.86 CFTR CSF2 TLR4
36
Pertussis 38
11.85 IL10 SFTPA2 TLR4 TNF
37
Dendritic Cells Developmental Lineage Pathway 66
11.82 CD209 CSF2 IFNG IL10 TLR9 TNF
38
IL4-mediated signaling events 1
11.77 CCL17 IL10 IL4 IL5
39
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.68 CSF2 IFNG TNF
40
Interleukin-10 signaling 67
11.66 CCL3 CSF2 IL10 IL4 TNF
41
MSP-RON Signaling 65
11.63 IFNG TLR2 TLR4 TNF
42
Legionellosis 38
11.62 TLR2 TLR4 TNF
43
Th2 Differentiation Pathway 66
11.62 CCL17 IFNG IL10 IL4 IL5
44
Microglia Activation During Neuroinflammation: Microglia Polarization 66
11.55 CCL17 CCL3 CSF2 IFNG IL10 IL4
45
Malaria 38
11.54 IFNG IL10 TLR2 TLR4 TLR9 TNF
46
African trypanosomiasis 38
11.5 IFNG IL10 TLR9 TNF
47
Development and heterogeneity of the ILC family 1
11.43 IFNG IL4 IL5 TNF
48
IL-10 Pathway 65
11.42 IL10 TLR4 TNF
49
Inflammatory Response Pathway 1
11.39 IFNG IL4 IL5
50
OX40 Pathway 65
11.33 IFNG IL10 IL4 IL5
Sources

GO Terms for Aspergillosis

About this section

Cellular components related to Aspergillosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.77 CCL17 CCL3 CSF2 ELANE IFNG IL10
2 cell surface GO:0009986 9.7 CD209 CFTR ELANE MBL2 TLR2 TLR4
3 extracellular region GO:0005576 9.5 CCL17 CCL3 CD209 CSF2 ELANE IFNG
4 collagen trimer GO:0005581 9.43 MBL2 SFTPA2 SFTPD

Biological processes related to Aspergillosis according to GeneCards Suite gene sharing:

(show top 50) (show all 65)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.99 TLR2 TLR4 TLR9 TNF
2 cellular response to interferon-gamma GO:0071346 9.96 CCL17 CCL3 TLR2 TLR4
3 defense response to bacterium GO:0042742 9.95 ELANE IL10 MBL2 SFTPD TLR4 TLR9
4 positive regulation of interleukin-6 production GO:0032755 9.93 TLR2 TLR4 TLR9 TNF
5 positive regulation of inflammatory response GO:0050729 9.92 CCL3 TLR2 TLR4 TLR9 TNF
6 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.91 TLR2 TLR4 TLR9 TNF
7 positive regulation of JNK cascade GO:0046330 9.9 TLR4 TLR9 TNF
8 positive regulation of tumor necrosis factor production GO:0032760 9.9 CCL3 TLR2 TLR4 TLR9
9 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.89 CSF2 IFNG IL4
10 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.89 TLR4 TLR9 TNF
11 positive regulation of nitric oxide biosynthetic process GO:0045429 9.88 IFNG PTX3 TLR4 TNF
12 positive regulation of B cell proliferation GO:0030890 9.88 IL4 IL5 TLR4 TLR9
13 lipopolysaccharide-mediated signaling pathway GO:0031663 9.86 CCL3 TLR2 TLR4 TNF
14 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.85 TLR2 TLR4 TLR9
15 negative regulation of interleukin-6 production GO:0032715 9.85 IL10 TLR4 TLR9 TNF
16 positive regulation of interferon-beta production GO:0032728 9.84 TLR2 TLR4 TLR9
17 positive regulation of interleukin-8 production GO:0032757 9.84 TLR2 TLR4 TLR9 TNF
18 negative regulation of osteoclast differentiation GO:0045671 9.83 CCL3 IL4 TLR4
19 positive regulation of interleukin-10 production GO:0032733 9.82 TLR2 TLR4 TLR9
20 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.81 TLR2 TLR4 TLR9
21 regulation of cytokine secretion GO:0050707 9.81 TLR2 TLR4 TLR9
22 positive regulation of interleukin-12 production GO:0032735 9.81 IFNG TLR2 TLR4 TLR9
23 I-kappaB phosphorylation GO:0007252 9.8 TLR2 TLR4 TLR9
24 positive regulation of podosome assembly GO:0071803 9.79 CSF2 IL5 TNF
25 response to molecule of bacterial origin GO:0002237 9.79 IL10 TLR2 TLR9
26 positive regulation of chemokine production GO:0032722 9.78 TLR2 TLR4 TLR9 TNF
27 macrophage chemotaxis GO:0048246 9.74 CCL3 SFTPD
28 positive regulation of MHC class II biosynthetic process GO:0045348 9.74 IL10 IL4 TLR4
29 cell activation GO:0001775 9.73 CCL3 TLR2
30 dendritic cell differentiation GO:0097028 9.73 CSF2 IL4
31 negative regulation of interleukin-17 production GO:0032700 9.73 IFNG TLR4
32 macrophage activation GO:0042116 9.73 CSF2 TLR4
33 surfactant homeostasis GO:0043129 9.72 SFTPA2 SFTPD
34 cellular response to lipoteichoic acid GO:0071223 9.72 TLR2 TLR4
35 opsonization GO:0008228 9.72 MBL2 PTX3
36 endothelial cell apoptotic process GO:0072577 9.71 IL10 TNF
37 positive regulation of interferon-beta biosynthetic process GO:0045359 9.71 TLR4 TLR9
38 negative regulation of interleukin-8 production GO:0032717 9.71 IL10 TLR9
39 negative regulation of cytokine secretion involved in immune response GO:0002740 9.71 IL10 TNF
40 positive regulation of interleukin-18 production GO:0032741 9.7 TLR2 TLR9
41 positive regulation of interleukin-23 production GO:0032747 9.7 CSF2 IFNG
42 tumor necrosis factor production GO:0032640 9.69 TLR2 TLR9
43 positive regulation of toll-like receptor signaling pathway GO:0034123 9.69 TLR2 TLR9
44 regulation of isotype switching GO:0045191 9.68 IL10 IL4
45 response to yeast GO:0001878 9.68 ELANE PTX3
46 type 2 immune response GO:0042092 9.68 IL10 IL4
47 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.68 IFNG TNF
48 receptor biosynthetic process GO:0032800 9.67 IL10 TNF
49 negative regulation of growth of symbiont in host GO:0044130 9.67 ELANE IL10 MBL2 TNF
50 positive regulation of cellular response to macrophage colony-stimulating factor stimulus GO:1903974 9.66 TLR2 TLR4

Molecular functions related to Aspergillosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.67 CSF2 IL10 IL4 IL5
2 lipopolysaccharide binding GO:0001530 9.46 SFTPA2 SFTPD TLR2 TLR4
3 virion binding GO:0046790 9.43 CD209 PTX3
4 signaling pattern recognition receptor activity GO:0008329 9.43 CLEC7A TLR2 TLR9
5 carbohydrate binding GO:0030246 9.43 CD209 CLEC1A CLEC7A MBL2 SFTPA2 SFTPD
6 lipopolysaccharide receptor activity GO:0001875 9.32 TLR2 TLR4
7 cytokine activity GO:0005125 9.23 CCL17 CCL3 CSF2 IFNG IL10 IL4
8 protein binding GO:0005515 10.33 CCL17 CCL3 CD209 CFTR CLEC7A CSF2
Sources

Sources for Aspergillosis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....